Clinical Study of JS201 in Patients With Advanced Malignant Tumors
Status:
Recruiting
Trial end date:
2023-07-07
Target enrollment:
Participant gender:
Summary
This is an open label, phase I clinical study to evaluate the safety, tolerability,
pharmacokinetic (PK) profile, pharmacodynamic (PD) profile, immunogenicity and preliminary
efficacy of JS201 in the patients with advanced malignant tumors who have progression after
or on the standard of care, or no effective standard therapeutic regimen. This study is
divided into three periods: dose-escalation period, dose expansion period, and clinical
expansion period.